nad has been researched along with Burkitt Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Stefano, G; Govoni, M; Manerba, M; Vettraino, M | 1 |
| Salord, J; Schuber, F | 1 |
2 other study(ies) available for nad and Burkitt Lymphoma
| Article | Year |
|---|---|
Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.
Topics: Adenosine Triphosphate; Burkitt Lymphoma; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Isocoumarins; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Lactic Acid; NAD; Proto-Oncogene Proteins c-myc; Signal Transduction; Sirtuin 1; Time Factors | 2013 |
In vitro drug delivery mediated by ecto-NAD+-glycohydrolase ligand-targeted liposomes.
Topics: Ammonium Chloride; Animals; Antineoplastic Agents; Burkitt Lymphoma; Cell Division; Cell Line; Deoxyuridine; Drug Carriers; Fibroblasts; Humans; Kinetics; Liposomes; Methotrexate; Mice; N-Glycosyl Hydrolases; NAD; NAD+ Nucleosidase; Sulfhydryl Compounds; Tumor Cells, Cultured | 1988 |